The Amsterdam District Court ruled that the representative organization Stichting Farma Ter Verantwoording is admissible in its collective action against pharmaceutical giant AbbVie. The case now moves on to the merits phase, in which the court will assess whether Abbvie abused its dominant position and violated human rights by charging excessive prices for its Humira medicine.
We are proud to share that Lindenbaum has been ranked in the Legal 500 as one of the leading firms in the Netherlands in the EMEA 2024 rankings. The firm has been ranked in the "Dispute resolution: class actions category", and is noted as a “firm to watch” in the "Dispute Resolution: Commercial Litigation" and "EU and Competition categories".
The International Bar Association will be hosting their three-day Annual Litigation Forum in Amsterdam from 17 to 19 April 2024. This year the Forum will revolve around key litigation themes such as The Hague Convention, cross-border enforcement, the handling of expert witnesses, and trends in class actions. Lindenbaum will be sponsoring the conference diner, and our partners Guido Vergouwen and Damiën Berkhout will be delegates at the Forum.
Lindenbaum is pleased to announce that it is further expanding its antitrust litigation practice with the arrival of Simon Mineur (associate) and Niels Wessel (paralegal).
Lindenbaum is pleased to announce that it is expanding its litigation practice with the arrival of Noor Hogerzeil (counsel) and Serap Akbaba (legal trainee). Lindenbaum is also pleased to announce the promotion of Dizzy van Duijn to the role of associate (advocaat-stagair).
Lindenbaum B.V.
Concertgebouwplein 13-H
1071 LL, Amsterdam
